Klin Farmakol Farm. 2005;19(1):67-71

Infliximab in clinical treatment

MUDr. Vladimír Zbořil CSc
III. interní klinika gastroenterologická, FN Brno-Bohunice

Infliximab belongs to the group of so name biological therapy. It is human monoclonal antibody against tumor necrosis factor alpha. It consist of 25% mice a and 75% human sequention. The main contemporary indication´s for its clinical use are rheumatoid arthritis, rheumatoid spondylitis (ancylosing spondylitis) and Crohn´s disease.

Keywords: Key words: TNF – tumor necrosis factor, Crohn´s disease, rheumathoid arthritis, rheumathoid spondylitis, IL – interleukin´s.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zbořil V. Infliximab in clinical treatment. Klin Farmakol Farm. 2005;19(1):67-71.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Sands BE. Biologic therapy for inflammatory bowel disease. Inflammatory bowel disease, 1997; 3: 95-113. Go to original source... Go to PubMed...
    2. Ardizzone S, Bianchi Porro G. Inflammatory bowel disease: new insights into pathogenesis and treatment. Journal of J Int Med, 2002; 252: 475-496. Go to original source... Go to PubMed...
    3. Terr AI. Mechanismy zánětu. In: Stites DP, Terr AI. Základní a klinická imunologie. Victoria Publishing, 1991: 122-129.
    4. Maini R, ST Calir, EW, Breedweld F, et al. for the ATTRACT Study Group: Infliximab (chimeric anti-tumor necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant medication methotrexate: a randomised phase III trial. Lancet, 1999; 354: 1932-1939. Go to original source... Go to PubMed...
    5. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: randomised controlled multicentre trial. Lancet, 2002; 359: 1187-1193. Go to original source... Go to PubMed...
    6. Hanauer SB. Maintanance infliximab for Crohn´s disease. The ACCENT I randomized trial. Lancet, 2002; 359, 4: 1541-1549. Go to original source... Go to PubMed...
    7. Sands B. Infliximab maintanance therapy for fistulating Crohn´s disease (ACCENT II). N Engl J Med, 2004; 350, 9: 876-885. Go to original source... Go to PubMed...
    8. Rutgeerts P. Comparison of Schedule and episodic treatment stategies of schedule infliximab in Crohn´s disease. Gastroenterology, 2004; 126: 402-413. Go to original source... Go to PubMed...
    9. Ryan BM, Russel GMVM, Schurgers L, et al. Effect of antitumor necrosis factor-alpha therapy on bone turnover in patiens with active Crohn´s disease: a prospective study. Aliment Pharmacol Ther, 2004; 20: 851-857. Go to original source... Go to PubMed...
    10. Marshal L, Haens GD, Van Asshe G, et al. The risk of post-operative complications associated with infliximab therapy for Crohn´s disease: a controlled cohort study. Aliment Pharmacol Ther, 2004; 19: 749-754. Go to original source... Go to PubMed...
    11. Colomobel JF, Loftus Event, Tremaine WJ. Perioperative infliximab and/or immunomodulatory therapy is not associated with increased postoperative complications in Crohn´s disease. Gastroenterology, 2002; 124:A521 (abstract). Go to original source...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.